高级检索
    汪颖, 张晓祺. DAWNA-1研究：达尔西利联合氟维司群治疗HR+/HER2-晚期乳腺癌的疗效分析[J]. 循证医学, 2023, 23(2): 83-87. DOI: 10.12019/j.issn.1671-5144.2023.02.004
    引用本文: 汪颖, 张晓祺. DAWNA-1研究：达尔西利联合氟维司群治疗HR+/HER2-晚期乳腺癌的疗效分析[J]. 循证医学, 2023, 23(2): 83-87. DOI: 10.12019/j.issn.1671-5144.2023.02.004
    shu
    WANG Ying, ZHANG Xiao-qi. DAWNA-1 Study: Efficacy Analysis of Dalpiciclib Plus Fulvestrant in Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 83-87. DOI: 10.12019/j.issn.1671-5144.2023.02.004
    Citation: WANG Ying, ZHANG Xiao-qi. DAWNA-1 Study: Efficacy Analysis of Dalpiciclib Plus Fulvestrant in Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 83-87. DOI: 10.12019/j.issn.1671-5144.2023.02.004
    shu

    DAWNA-1研究：达尔西利联合氟维司群治疗HR+/HER2-晚期乳腺癌的疗效分析

    DAWNA-1 Study: Efficacy Analysis of Dalpiciclib Plus Fulvestrant in Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

      摘要
      • HTML全文
      • 参考文献(5)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回